TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on TG Therapeutics, with five buys, three holds and one sell among nine firms. The average 12-month price target is $63.00, with targets ranging from $20 to $83.
• TG Therapeutics reported quarterly revenue of $240.34 million, up 70.2% year over year and above estimates, but earnings of $0.05 per share missed expectations of $0.31.
• The stock recently traded at $56.09, near its 12-month high of $59.30, while hedge funds and other institutional investors own 58.58% of the company.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received a consensus recommendation of "Hold" from the nine ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $63.00.

Several brokerages recently issued reports on TGTX. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Zacks Research upgraded TG Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, June 1st. Jefferies Financial Group restated a "buy" rating and issued a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. Bank of America boosted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research report on Tuesday, July 7th. Finally, HC Wainwright restated a "buy" rating and set a $78.00 target price on shares of TG Therapeutics in a report on Tuesday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter valued at approximately $25,000. EverSource Wealth Advisors LLC increased its position in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 365 shares in the last quarter. Hantz Financial Services Inc. increased its position in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 560 shares in the last quarter. Truvestments Capital LLC raised its holdings in shares of TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter worth $52,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 3.3%

Shares of TG Therapeutics stock opened at $56.09 on Wednesday. The company has a 50-day moving average of $53.41 and a two-hundred day moving average of $42.28. TG Therapeutics has a 12-month low of $26.76 and a 12-month high of $59.30. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The stock has a market cap of $8.59 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 2.33 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to analysts' expectations of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics's revenue was up 70.2% compared to the same quarter last year. During the same period last year, the firm earned $0.17 EPS. On average, research analysts anticipate that TG Therapeutics will post 0.92 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source